Following recent discussions with the company for the appraisal of Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811], please be advised that this topic will now be appraised as a Multiple Technology Appraisal.
For information, the appraisal is now anticipated to begin during late October 2021; with an anticipated evidence submission deadline to NICE of mid- February 2022.